Overview

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether SLx-4090 in combination with statin therapy will reduce LDL-C in patients with hyperlipidemia more effectively than statin therapy alone.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kadmon Corporation, LLC
Treatments:
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Criteria
Inclusion Criteria:

- LDL-C > or = 100 mg/dL

- On stable statin therapy for at least 6 weeks

Exclusion Criteria:

- Coronary heart disease or risk factors for CHD